Anti-oxidant and Metabolic Phenotype in Regulating Tumor Specific T cell Memory Response

抗氧化和代谢表型调节肿瘤特异性 T 细胞记忆反应

基本信息

  • 批准号:
    9917102
  • 负责人:
  • 金额:
    $ 52.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-12-01 至 2024-11-30
  • 项目状态:
    已结题

项目摘要

ABSTRACT New strategies to improve adoptive cell therapy (ACT) protocols are now emerging to enhance in vivo persistence of adoptively transferred tumor epitope specific T cells and overcome tumor-induced immunosuppression. Our preliminary data suggests that there is a direct correlation between the long-lived central memory T cells (Tcm) and its anti-oxidant capacity. Overexpression of thioredoxin-1 (Trx), a key molecule that regulates cell-surface thiols (c-SH), resulted in increased Tcm phenotype in T cells obtained from TCR transgenic mouse crossbred with Trx transgenic mouse, or engineering human T cells with retroviral vector with TCR and Trx together. Further, a quantification of the metabolites within Pmel vs. Pmel-Trx cells showed that metabolites from pentose-phosphate pathway (PPP) and tricarboxylic acid cycle (TCA) intermediate alpha-ketoglutarate (α-KG) were significantly higher in Pmel-Trx T cells as compared to Pmel cells. While reductive intermediates generated by PPP are important to overcome oxidative stress, recent reports have shown that α-KG is important in extending the cellular lifespan and regulating pluripotency of stem cells. These preliminary observations lead us to hypothesize that “the presence of Trx drives tumor reactive T cells to a c-SHhi phenotype, which not only exhibits enhanced anti-oxidant phenotype, but regulates a combination of events including post-translational modifications, and epigenetic stability that lead to metabolically fit anti-tumor T cells”. We propose the following specific aims: 1) To determine how the level of thiol/thioredoxin on the surface of T cells regulates the generation of tumor reactive Tcm/Tscm cells in vivo, 2) To determine how changes in the metabolic pathways and metabolites in T cells regulate the generation of tumor reactive Tcm/Tscm in vivo, 3) To determine if modulation of reduced thiols and/or metabolites results in generation of tumor reactive TCR transduced human T cells with functional memory phenotype. We believe that our studies are innovative and will uncover important aspects that need to be considered when generating tumor specific Tcm/Tscm cells for ACT.
抽象的 改善自适应细胞疗法(ACT)方案的新策略现在正在出现以增强体内 适当转移的肿瘤表位特异性T细胞的持久性并克服了肿瘤诱导的 免疫抑制。我们的初步数据表明,长寿之间存在直接相关 中央记忆T细胞(TCM)及其抗氧化能力。硫氧还蛋白-1(TRX)的过表达,钥匙 调节细胞表面硫醇(C-SH)的分子,导致TCM表型增加了T细胞中的TCM表型 TCR转基因小鼠用TRX转基因小鼠或逆转录病毒工程人T细胞杂交 使用TCR和TRX的向量。此外,对PMEL与PMEL-TRX细胞中的代谢产物进行定量 表明来自五磷酸五磷酸途径(PPP)和三碳酸周期(TCA)的代谢产物 与PMEL相比 细胞。虽然PPP产生的减少中间体对于克服氧化物应激很重要,但最近 报告表明,α-kg对于延长细胞寿命和控制多能性很重要 干细胞。这些初步观察结果使我们假设“ TRX的存在驱动肿瘤 反应性T细胞对C-SHHI表型,该表型不仅表现出增强的抗氧化表型,而且调节 包括翻译后修饰和表观遗传稳定性在内的事件的组合,导致 代谢上拟合的抗肿瘤T细胞”。我们提出以下特定目的:1)确定如何确定 T细胞表面上的硫醇/硫氧还蛋白调节体内肿瘤反应性TCM/TSCM细胞的产生,2) 确定T细胞中代谢途径和代谢产物的变化如何调节产生 肿瘤反应性TCM/TSCM体内,3)确定降低硫醇和/或代谢物的调节是否导致 肿瘤反应性TCR的产生用功能性记忆表型翻译了人类T细胞。我们相信 我们的研究具有创新性,并将发现生成时需要考虑的重要方面 用于ACT的肿瘤特异性TCM/TSCM细胞。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shikhar Mehrotra其他文献

Shikhar Mehrotra的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shikhar Mehrotra', 18)}}的其他基金

Increasing Thiols for Improving T cell Immunotherapy
增加硫醇以改善 T 细胞免疫治疗
  • 批准号:
    10603006
  • 财政年份:
    2022
  • 资助金额:
    $ 52.24万
  • 项目类别:
Intersections of RNA-binding proteins and T-cells in oral epithelial plasticity
RNA结合蛋白和T细胞在口腔上皮可塑性中的交叉点
  • 批准号:
    10417171
  • 财政年份:
    2020
  • 资助金额:
    $ 52.24万
  • 项目类别:
Understanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cells
了解强效抗肿瘤 T 细胞中的代谢和表观遗传交叉对话
  • 批准号:
    10400117
  • 财政年份:
    2020
  • 资助金额:
    $ 52.24万
  • 项目类别:
Intersections of RNA-binding proteins and T-cells in oral epithelial plasticity
RNA结合蛋白和T细胞在口腔上皮可塑性中的交叉点
  • 批准号:
    10178000
  • 财政年份:
    2020
  • 资助金额:
    $ 52.24万
  • 项目类别:
Programming Metabolically Fit TILs for Immunotherapy
为免疫疗法编程适合代谢的 TIL
  • 批准号:
    9906726
  • 财政年份:
    2020
  • 资助金额:
    $ 52.24万
  • 项目类别:
Understanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cells
了解强效抗肿瘤 T 细胞中的代谢和表观遗传交叉对话
  • 批准号:
    10599308
  • 财政年份:
    2020
  • 资助金额:
    $ 52.24万
  • 项目类别:
Understanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cells
了解强效抗肿瘤 T 细胞中的代谢和表观遗传交叉对话
  • 批准号:
    10163144
  • 财政年份:
    2020
  • 资助金额:
    $ 52.24万
  • 项目类别:
Intersections of RNA-binding proteins and T-cells in oral epithelial plasticity
RNA结合蛋白和T细胞在口腔上皮可塑性中的交叉点
  • 批准号:
    10632129
  • 财政年份:
    2020
  • 资助金额:
    $ 52.24万
  • 项目类别:
Programming Metabolically Fit TILs for Immunotherapy
为免疫疗法编程适合代谢的 TIL
  • 批准号:
    10822377
  • 财政年份:
    2020
  • 资助金额:
    $ 52.24万
  • 项目类别:
Anti-oxidant and Metabolic Phenotype in Regulating Tumor Specific T cell Memory Response
抗氧化和代谢表型调节肿瘤特异性 T 细胞记忆反应
  • 批准号:
    10300448
  • 财政年份:
    2019
  • 资助金额:
    $ 52.24万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 52.24万
  • 项目类别:
ST8Sia6 modulation of diabetes
ST8Sia6 调节糖尿病
  • 批准号:
    10617387
  • 财政年份:
    2021
  • 资助金额:
    $ 52.24万
  • 项目类别:
ST8Sia6 modulation of diabetes
ST8Sia6 调节糖尿病
  • 批准号:
    10414792
  • 财政年份:
    2021
  • 资助金额:
    $ 52.24万
  • 项目类别:
ST8Sia6 modulation of diabetes
ST8Sia6 调节糖尿病
  • 批准号:
    10311393
  • 财政年份:
    2021
  • 资助金额:
    $ 52.24万
  • 项目类别:
Therapeutic applications of CD4+ T cells specific for oncogenic driver mutations
致癌驱动突变特异性 CD4 T 细胞的治疗应用
  • 批准号:
    9977672
  • 财政年份:
    2020
  • 资助金额:
    $ 52.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了